Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids
暂无分享,去创建一个
R. Schoemaker | L. Zuurman | A. Strougo | L. Zuurman | C. Roy | JL Pinquier | JMA van Gerven | AF Cohen | RC Schoemaker | J. V. van Gerven | A. Strougo | A. Cohen | C. Roy | J. Pinquier
[1] A. Howlett,et al. CB1 receptor–G protein association , 2001 .
[2] M. Wall,et al. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. , 1981, Journal of clinical pharmacology.
[3] D. Kendall,et al. Cardiovascular effects of cannabinoids. , 2002, Pharmacology & therapeutics.
[4] P. Netter. Dopamine challenge tests as an indicator of psychological traits , 2006, Human psychopharmacology.
[5] M. Wall,et al. The Metabolism of Δ9‐Tetrahydrocannabinol and Related Cannabinoids in Man , 1981 .
[6] M. Wall,et al. Intravenous Injection in Man of Δ9-Tetrahydrocannabinol and 11-OH-Δ9-Tetrahydrocannabinol , 1972, Science.
[7] C. Breivogel,et al. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. , 2000, Molecular pharmacology.
[8] A. Cohen,et al. Pharmacokinetic/pharmacodynamic Assessment of Tolerance to Central Nervous System Effects of a 3 mg Sustained Release Tablet of Rilmenidine in Hypertensive Patients , 2004, Journal of psychopharmacology.
[9] M. Danhof,et al. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.
[10] L B Sheiner,et al. Pharmacokinetic and pharmacodynamic modeling in vivo. , 1981, Critical reviews in bioengineering.
[11] J. Gerven,et al. The Application of the Principles of Clinical Drug Development to Pharmacological Challenge Tests of the Serotonergic System , 2004, Journal of psychopharmacology.
[12] S. Heishman,et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. , 2001, Archives of general psychiatry.
[13] G. Barnett,et al. Marijuana effect and delta‐9‐tetrahydrocannabinol plasma level , 1984, Clinical pharmacology and therapeutics.
[14] U. Ebert,et al. Scopolamine model of dementia: electroencephalogram findings and cognitive performance , 1998, European journal of clinical investigation.
[15] A. Howlett,et al. CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. , 2001, European journal of biochemistry.
[16] L B Sheiner,et al. Estimating population kinetics. , 1982, Critical reviews in biomedical engineering.
[17] A. V. D. Does,et al. The effects of tryptophan depletion on mood and psychiatric symptoms. , 2001 .
[18] R. Pertwee. Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.
[19] A F Cohen,et al. Estimating impossible curves using NONMEM. , 2003, British journal of clinical pharmacology.
[20] G. Ertl,et al. Cannabinoids Acting on CB1 Receptors Decrease Contractile Performance in Human Atrial Muscle , 2003, Journal of cardiovascular pharmacology.
[21] A. Bond,et al. The use of analogue scales in rating subjective feelings , 1974 .
[22] M Danhof,et al. Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.
[23] L B Sheiner,et al. Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.
[24] S. Rietbrock,et al. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. , 1997, International journal of clinical pharmacology and therapeutics.
[25] France Mentré,et al. Modelling and Simulation in the Development and use of Anti-Cancer Agents: An Underused Tool? , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[26] R. Gieschke,et al. Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[27] L Aarons,et al. Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[28] R. Rapaka,et al. Pharmacokinetics and disposition of cannabinoids. , 1987, NIDA research monograph.
[29] S. M. Owens,et al. Kinetic study of smoking marijuana , 1982, Journal of Pharmacokinetics and Biopharmaceutics.
[30] S. Goldberg,et al. Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence , 2005, Journal of Pharmacology and Experimental Therapeutics.
[31] A F Cohen,et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans , 2008, Journal of psychopharmacology.
[32] J. Hartigh,et al. Effects of intravenous temazepam. II. A study of the long‐term reproducibility of pharmacokinetics, pharmacodynamics, and concentration‐effect parameters , 1994, Clinical pharmacology and therapeutics.
[33] B. M. Wright. A simple mechanical ataxia-meter. , 1971, The Journal of physiology.
[34] Franjo Grotenhermen,et al. Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.
[35] B. Sadler,et al. Metabolism, disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women , 1983, Clinical pharmacology and therapeutics.
[36] Wright Bm. A simple mechanical ataxia-meter. , 1971 .
[37] L. Hollister,et al. Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking , 1980, Clinical pharmacology and therapeutics.
[38] A. Ameri. The effects of cannabinoids on the brain , 1999, Progress in Neurobiology.
[39] R. Hampson,et al. Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.
[40] M. Widman. Biliary excretion of ?1-tetrahydrocannabinol and its metabolites in the rat , 1974 .